The pulmonary arterial hypertension (PAH) patients have high rate of mortality due to right ventricle (or ventricular) (RV) failures. A lot of research work is being carried out in the area, however no treatment is available that could contrast the rise in mortality rates in PAH patients. β1-adrenoceptor blockers (β-blockers, BB) reduced mortality in left heart failure, but they do not explored much at clinical level. Recent studies suggest β-blockers might be beneficial in PAH; however the mechanisms remain unknown. The present review article would put light on all these aspects of PAH along with latest ways for the management of PAH.